Clinical question What are the benefits and harms of sodium-glucose cotransporter 2 (SGLT-
2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists when added to usual …

Background: Guidelines recommend sodium–glucose cotransporter-2 (SGLT2) inhibitors
and glucagon-like peptide-1 (GLP1) receptor agonists as second-line therapy for patients …

Abstract Type 2 Diabetes Mellitus (T2D) is a chronic disease with a pandemic incidence
whose pathogenesis has not yet been clarified. Raising evidence highlighted the role of …

Glucagon-like peptide-1 receptor agonists reduce albuminuria and may stabilize the
estimated glomerular filtration rate (eGFR) in people with type 2 diabetes (T2D). In this post …

Agonism of the glucagon-like peptide-1 receptor (GLP-1R) results in glycemic lowering and
body weight loss and is a therapeutic strategy to treat type 2 diabetes (T2D) and obesity. We …

Resumen La Sociedad Española de Arteriosclerosis tiene entre sus objetivos contribuir al
mayor y mejor conocimiento de la enfermedad vascular, su prevención y su tratamiento. Es …

Metformin is a biguanide that is used as first-line treatment of type 2 diabetes mellitus and is
effective as monotherapy and in combination with other glucose-lowering medications. It is …

Previous guidelines for the treatment of people with type 2 diabetes mellitus (T2D) have
relied heavily upon rigid algorithms for the sequential addition of pharmacotherapies to …

Description: The American Diabetes Association (ADA) updates the Standards of Medical
Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other …

First developed in 1990, the Agatston coronary artery calcium (CAC) score is an
international guideline-endorsed decision aid for further risk assessment and personalized …